摘要
目的:评价利伐沙班与依诺肝素预防全髋关节置换术(THA)后静脉血栓栓塞症的成本-效果,为临床用药决策提供经济学依据。方法:建立THA后预防静脉血栓栓塞症的决策树模型,参考随机对照试验的Meta分析研究成果确定模型中各节点相关事件发生率及治疗有效率,运行数据模型得出成本-效果比。结果:利伐沙班预防成本969.36元,治疗有效率98.9%;依诺肝素预防成本1 819.87元,治疗有效率96.3%。两组的成本-效果比分别为980.14和1 889.79。结论:利伐沙班预防THA术后静脉血栓形成相比依诺肝素更具有经济优势。
Objective: To evaluate the cost-effectiveness of rivaroxaban and enoxaparin in preventing venous thromboembolism after total hip arthroplasty.Methods: The decision tree model of prevent venous thromboembolism after total hip arthroplasty was established,and the event probabilities used in the model were identified from the published literatures by meta-analysis.The cost-effectiveness ratio was calculated by data model.Results: The preventive cost of rivaroxaban was ￥ 969.36 and the effective rate was 98.9%.The preventive cost of enoxaparin was ￥ 1 819.87 and the effective rate was 96.3%.The cost-effectiveness of rivaroxaban was 980.14 and enoxaparin was 1 889.79.Conclusion: Rivaroxaban has economic advantages in preventing venous thrombosis after total hip arthroplasty when compared to enoxaparin.
作者
王声祥
赵可新
石蕊
任艳平
李楠
卢姗
Wang Shengxiang;Zhao Kexin;Shi Rui;Ren Yanping;Li Nan;Lu Shan(Department of Pharmacy,Hebei Petro China Central Hospital,Hebei Langfang 065000,China)
出处
《中国药师》
CAS
2019年第8期1457-1460,共4页
China Pharmacist
基金
2017年廊坊市科学技术研究与发展计划(编号:2017013052)
